Wall Street closes at a record for the first time since end of January
Edwards Lifesciences Corp (NYSE:EW) Chief Financial Officer Scott B. Ullem sold 13,000 shares of company stock on April 9, 2026, according to a Form 4 filing with the Securities and Exchange Commission. The sales totaled $1,040,544.
The filing reveals that Ullem sold 4,676 shares at prices ranging from $80.225 to $80.750 and 8,324 shares at prices ranging from $79.210 to $80.200.
On the same day, Ullem also exercised options to acquire 13,000 shares of Edwards Lifesciences common stock at a price of $59.2567, for a total value of $770,337.
Following these transactions, Ullem directly owns 39,699 shares and indirectly owns 266,318 shares of Edwards Lifesciences (NYSE:EW) through a trust.The insider sale comes as Edwards Lifesciences trades at a P/E ratio of 44 with a market capitalization of $45.6 billion. According to InvestingPro analysis, the stock appears undervalued at current levels, trading below its Fair Value. The company shows strong fundamentals, with 21 analysts recently revising earnings upwards for the upcoming period—one of several key insights available in the comprehensive Pro Research Report covering Edwards Lifesciences and 1,400+ other US equities.
In other recent news, Edwards Lifesciences reported its fourth-quarter 2025 earnings with an adjusted earnings per share (EPS) of $0.58, which did not meet analysts’ expectations of $0.62. However, the company achieved a revenue of $1.57 billion, surpassing the forecast of $1.55 billion and marking an 11.6% growth year-over-year. Stifel reiterated its Buy rating for Edwards Lifesciences, maintaining a price target of $110.00. Additionally, Edwards Lifesciences presented promising two-year data from its TRISCEND II trial, showing lower all-cause mortality with its EVOQUE transcatheter tricuspid valve replacement system. The trial also highlighted improvements in health status and quality of life without added device-related risk. Furthermore, the company announced its goal to help 2 million more patients access structural heart treatment by 2030 through its Every Heartbeat Matters initiative. This initiative has already impacted over 4 million underserved patients globally since 2014.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.